We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug & Device Products
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Publications
    • Webinar Training Pass
    • eCFR and Guidances
    • Books
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Boehringer Ingelheim and Eli Lilly Announce Resubmission of NDA for Type 2 Diabetes Drug

Boehringer Ingelheim and Eli Lilly Announce Resubmission of NDA for Type 2 Diabetes Drug

Signing Paper
June 18, 2014

Boehringer Ingelheim and Eli Lilly announced they have resubmitted an NDA for an investigational type 2 diabetes treatment, a sodium glucose co-transporter-2 (SGLT2) inhibitor, empagliflozin.

The Class 1 resubmission comes on the heels of a complete response letter issued by the FDA that referred to deficiencies previously seen at a BI facility where empagliflozin will be manufactured.

The FDA did not ask Boehringer Ingelheim to complete any new clinical trials to support the approval of the application, the Germany-based drugmaker said.

An investigational SGLT2 inhibitor, empagliflozin is being studied for the reduction of blood glucose levels in adult patients with diabetes. The SGLT2 inhibitor works by blocking glucose re-absorption in the kidney, removing excess glucose through the urine.

Empagliflozin was evaluated in one of the largest clinical studies in its class, BI said, consisting of 10 multinational clinical trials, involving more than 13,000 adults with type 2 diabetes.

Over a two year period, empagliflozin in combination with certain other diabetes therapies showed reductions in blood glucose, body weight and blood pressure compared with glimepiride, the drugmaker said. — Kellen Owings

Subscribe to Drug Industry Daily for complete coverage of the pharmaceutical industry. Click here for more information.

Pharmaceuticals Submissions and Approvals

Upcoming Events

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 13Jul

    FDA Ad and Promo Enforcement Trends: Past, Present and Future

  • 28Jul

    EU-MDR’s Growing Pains: Are You Current with the Latest Developments?

  • 28Jul

    Is Your Product a Drug or Device — and Does It Matter?: A Recent Appeals Court Decision Says It Does

  • 02Aug

    Medical Device Cybersecurity: Understand the Latest Developments

  • 03Aug

    Pharmaceutical Process Validation: Best Practices for Success

Featured Products

  • FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

    FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

  • Selecting and Implementing Electronic Document Management Systems in the EU

    Selecting and Implementing Electronic Document Management Systems in the EU

Featured Stories

  • Okami Medical’s LOBO-7 and LOBO-9 Vascular Occluders Cleared

  • FDA Puts Clinical Hold on Astellas Late-Onset Pompe Disease Clinical Trial

  • FDA Provides Update on GE Healthcare’s Recall of Its Carescape R860 Ventilators

  • Gilead Resubmits NDA for Lenacapavir Following Complete Response Letter

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Toll free 888.838.5578

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing